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IL-1 pretreatment prolongs survival in lethal infection in normal and in neutropenic mice. We investigated whether 
this protection occurs by interference with deleterious cytokine effects. The effect of IL-1 pretreatment on con­
centrations of IL-1 a, IL-1/3, IL-6, and TNF-a circulating in vivo and the ex vivo cytokine production capacity of 
macrophages was assessed in uninfected, non-neutropenic and neutropenic Swiss mice, in Swiss mice infected 
with Klebsiella pneumoniae (non-neutropenic mice) or Pseudomonas aeruginosa (neutropenic mice), and in neu­
tropenic C3H/HeN and C3H/HeJ mice infected with P. aeruginosa. In Swiss and C3H/HeN mice, IL-1 pretreatment 
enhanced survival and reduced circulating TNF-a and IL-6 as well as LPS-stimulated production of IL-1 a: and 
TNF-a. In C3H/HeJ mice, a lack of IL-1-induced protection was associated with low cytokine concentrations and 
production. In contrast, up-regulation of mRNA for the IL-1 receptor antagonist (IL-1 Ra) was observed in several 
organs of IL-1-pretreated mice, suggesting that IL-1 Ra could attenuate deleterious IL-1 effects. In addition, IL-1 
pretreatment down-regulated steady state mRNA for the type I IL-1 R and the type I TNFR in several organs at the 
time of infection, suggesting desensitization of target cells as an additional mechanism of IL-1 -induced protection. 
We conclude that the IL-1-induced protection is at least partially mediated by down-regulating cytokine produc­
tion, and that the induction of IL-1 Ra and the desensitization of target cells by receptor down-modulation may also 
contribute to this phenomenon. The Journal o f  Immunology, 1994, 153: 5772.
T wo 17-kDa IL-1 proteins (IL -la  and IL-1/3) pro­
duced by a variety of cell types, possess a wide 
spectrum of biologic effects (1). In animals, ad­
ministration of IL-1 has been shown to enhance nonspe­
cific resistance to bacteria, fungi, and plasmodia (2, 3). For 
example, pretreatment with a low dose (3 to 30 n g /kg) of 
recombinant human IL-1/3 (rhIL-1/3)2 24 h before a lethal 
Gram-negative infectious challenge enhances survival of 
normal and neutropenic mice (4, 5). The mechanism for
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this protection has only partially been clarified. A direct 
antimicrobial effect of IL-1 has been excluded in vitro (4), 
and whether IL-1 induces enhanced clearance of microor­
ganisms in vivo is controversial (4, 6 ). The protective ef­
fect of IL-1 in granulocytopenic mice argues against a ma­
jor role of neutrophils (2, 4, 7, 8). Glucocorticosteroids, 
eicosanoids, or cytokines such as IL-6 , IL-8 , and granu­
locyte macrophage-CSF do not mediate the IL-l-induced 
resistance to infection (9 -1 2 ). However, IL-l-induced 
TNF-a and IL-l-induced acute phase proteins play some 
role as mediators of the IL-1 effect (11, 12).
In severe Gram-negative infection, excessive produc­
tion of several cytokines including TNF-a, IL-1, IL-8 , and 
IFN-y, sometimes referred to as “lethal cytokinemia,” has 
been implicated in morbidity and lethality (13-15). To 
limit these deleterious effects, several counterregulatory 
mechanisms seem to exist: cytokine production may be 
inhibited (16), and host sensitivity to proinflammatory cy­
tokines may be reduced by production of endogenous in­
hibitors (17, 18) or tolerance of target cells, for example
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by down-regulation of receptors (19, 20). IL-1 might en 
hance host resistance to lethal infection by one or more of 
these mechanisms. IL-1 has been shown to induce its spe­
cific inhibitor, the competitive receptor antagonist (IL- 
lRa) in vivo in humans and in vitro (21-23). IL-1 is also 
capable of desensitizing to a lethal dose of LPS, TNF-a, 
and IL-1 (19) in vivo, and of reducing mRNA and protein 
levels for the type I IL-1R (IL-1RI) and the TNFR in sev­
eral types of cells in vitro (24, 25). In the present study, we 
have investigated whether these mechanisms play a role in 
the IL-l-induced protection to infection by assessing the 
effect of IL-1 pretreatment on in vivo and in vitro cytokine 
production and on organ mRNA levels of IL-1RI, TNFRI, 
and IL-IRa in infected animals.
Materials and Methods
Mice
Female outbred Swiss mice (weight, 20 to 25 g; TNO, Rijswijk, The 
Netherlands), female inbred C3H/HeJ and C3H/HeN mice (weight, 18 to 
25 g; Bomholt Gard, Ry, Denmark), and New Zealand white rabbits 
(from a local colony) were kept under specific pathogen-free conditions.
Materials
Recombinant murine and human IL-1/3 (rmIL-1/3 and rhIL-1/3) and poly­
clonal rabbit anti-murine IL-1 a  and IL-1/3 antisera were generously pro­
vided by Dr. P. Graber (Glaxo, Geneva, Switzerland); rmlL-lo: and 
rhlL-lo: were a kind gift of P. Lomedico, Hoffmann-La Roche (Nutley, 
NJ), and rmTNF-o: and rhT N F-a  were kindly donated by Dr. G. Adolf, 
Ernst-Boehringer Institut (Vienna, Austria). Inactivated IL-1/3 was pre­
pared by heating rhIL-1/3 at 95°C for 30 min. For in vivo administration, 
rhIL-1/3 or inactivated rhIL-1/3 (control treatment) was dissolved in pyrogen- 
free PBS, pH 7.4 (PBS), with 2% (v/v) mouse serum. Kind donations were 
received of cDNA for mIL-lRI (Dr. Ueli Gubler, Hofl'mann-La Roche Inc.), 
mTNFRI (Dr. D. Wallach, Weizmann Institute, Rehovot, Israel), mIL-IRa 
(Prof. A. S. Whitehead, University of Dublin, Dublin, Ireland) and chicken 
/3-actin (Dr. B. Huber, Tufts University, Boston, MA).
Radioimmunoassays for IL-1 a, //.-7/3, and TNF-a
RIAs for the murine cytokines were performed essentially as described 
previously (26). To optimize this RIA for murine plasma and cell culture 
samples, several modifications were necessary. Because standard curves 
in assay buffer and sample medium did not superimpose, the medium of 
the standards was chosen to be identical to that of the samples. To im­
prove sensitivity, the RIA was performed at 4°C, and the assay buffer in 
which the radiolabeled cytokines and second Ab were dissolved was 
changed to 6.25 mM sodium phosphate (pH 7.4), 12.75 mM EDTA, 0.25% 
BSA (ORHD21/22 grade; Sigma Chemical Co., St. Louis, MO), 0.02% so­
dium azide with addition of 0.1% (v/v) Triton-X, and 10,000 kallikrein- 
inactivating U/ml of aprotinin, with omission of normal rabbit serum.
The mean of triplicate standards was calculated, the value for non­
specific binding (without rabbit antiserum) was subtracted, and standard 
curves were fitted by weighted (27) nonlinear regression using a four- 
parameter logistic model (28)
IL-6 bioassay
IL-6 levels in serum were quantitated as hybridoma growth factor activity 
by using the IL-6-dependent murine hybridoma 7TD1 (a kind gift from 
J. van Snick, Ludwig Institute for Cancer Research, Brussels, Belgium) 
as described previously (29). Hybridoma growth factor activity resulting 
in half-maximal stimulation was arbitrarily defined as 1 U. The detection 
limit of the assay was 50 U/ml.
Experimental protocols
1) Survival experiments. To ascertain the effectiveness of  rhIL-1/3 pre­
treatments, enhancement of survival of P. aeruginosa infection was as­
sessed simultaneously with the preparation of samples for RIA and 
mRNA determinations. Because P. aeruginosa (ATCC 27853) does not 
kill normal mice, mice were rendered neutropenic (< 0 .5  X 10^ granu­
locytes per liter) by two s.c. injections of cyclophosphamide (ASTA 
Pharma, Frankfurt, Germany) on day - 4  and on day —1 (150 and 100 
mg/kg, respectively). On day — 1, 800 ng of hIL-1/3 or control treatment 
was injected i.p. (0.1 ml), and 24 h later, at time zero, a lethal challenge 
with 0.5 to 1 X 107 CFU of P. aeruginosa was given intramuscularly 
(i.m.) in the left thigh muscle. Six hours after the infection, gentamicin 
(120 mg/kg; Schering, Kenilworth, NJ) was administered s.c. to postpone 
the time of death, and thus accentuate the differences between treatment 
groups. Mortality was recorded for 48 h in the P. aeruginosa infection, 
because thereafter bone-marrow recovery starts to play a role, and also 
cyclophosphamide effects on cell types other than phagocytic cells may 
be involved.
2) Preparation o f samples for cytokine protein measurements. Mice 
were pretreated i.p. with 800 ng of rhIL-1/3 or control treatment 24 h 
before an i.m. infectious challenge with P. aeruginosa (neutropenic 
mice) or with 1 to 5 X 106 CFU K. pneumoniae ATCC 43816 (non- 
neutropenic mice). All bacterial challenges (0.1 ml per mouse) were pre­
pared by appropriate dilution of overnight cultures washed three times in 
saline. For assessments of circulating cytokines, blood was collected in­
dividually in EDTA-coated tubes on ice at several time points after in­
fection. Plasma was prepared within 1 h by 10 min centrifugation at 
400 X g at 4°C and stored at - 7 0 ° C .  For assessment of ex vivo cytokine 
production, resident peritoneal macrophages were harvested by rinsing 
the peritoneal cavity aseptically with cold PBS with 0.38% (w/v) sodium 
citrate. After centrifugation at 400 X g at 4°C, cells were resuspended in 
RPMI 1640 (Dutch modification; Flow Laboratories, Irvine, UK), con­
taining 1 mM pyruvate, 2 mM L-glutamine, and 100 ¡ig/ml gentamicin. 
After culture of peritoneal macrophages (10h cells/ml for 24 h) in 96-well 
microtiter plates in RPMI medium with or without LPS (from Esche­
richia coli serotype 055:B5; Sigma Chemical Co.) at a final concentration 
of 100 ng/ml, the culture supernatants were harvested, replaced by RPMI 
medium, and cells and supernatants were frozen at - 7 0 ° C .  Two more 
freeze-thaw cycles were performed before assay of cell-associated cyto­
kines to accomplish lysis.
3) Preparation o f tissues fo r mRNA assessments. Because surface pro­
tein expression of  murine IL-1 and TN F receptors are below detection 
limit for proper statistical analysis (30, 31), and the murine IL-IRa pro­
tein and specific Abs were not available, in vivo receptor expression and 
IL-IRa regulation were studied by using gene expression. At 4, 12, or 
24 h after i.p. administration of 800 ng of rhIL-1/3 or control injection i.p., 
Swiss mice were bled, killed by cervical dislocation, and the liver, spleen, 
kidneys, lungs, thymus, and brain were frozen immediately in liquid nitro­
gen, and stored at -7 0 °C .  Total RNA was extracted by using the guanidine- 
isothiocyanate-cesium chloride method (32). For Northern hybridization, 
performed to verify the integrity of RNA isolates, 20 ¿¿g of total RNA was 
subjected to electrophoresis in a 1.2% agarose-formaldehyde gel and trans­
ferred by capillar)' action to Hybond N + membrane (Amersham, Bucking­
hamshire, UK). RNA was fixed to the membrane with UV light as suggested 
by the manufacturer. Because all cDNA probes to be used were specific for 
the respective mRNA (24, 33-35), and analysis of both Northern and dot 
blots revealed a direct quantitative relationship (24,35), gene expression was 
analyzed by using dot blots. Dot blots (50 ¿ig and four twofold dilutions) also 
employed nylon membranes, and were sequentially probed with cDNA for 
mIL-lRI (2.2 kb), mIL-IRa (1.7 kb), mTNFRI (1.5 kb), and /3-actin. cDNAs 
were labeled with 32P by using a random-primed DNA labeling kit (Phar­
macia, Piscataway, NJ). Membranes were exposed at - 7 0 ° C  to Kodak 
XAR5 films with Dupont Cronex intensifying screens. Autoradiograms were 
scanned by laser densitometry (Ultroscan XL, Pharmacia LKB, Bromma, 
Sweden). Ratios of densities of mIL-IRa, mIL-lRI, and mTNFRI m RN A ’s 
after IL-1 vs control pretreatment (inactivated IL-1/3) were calculated and 
related to /3-actin by dividing by the ratios of /3-actin expression after IL-1 
vs control pretreatment.
Statistical analysis
Survival data were analyzed by use of  the log rank test (36). Comparisons 
of cytokine concentrations between treatment groups were made by the
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FIGURE 1. Survival of neutropenic Swiss, C3H/HeN, and 
C3H/HeJ mice of a lethal i.m. challenge with P. aeruginosa at 
t = 0 after i.p. pretreatment at - 2 4  h with 800 ng of IL-1 /3 or 
control pretreatment (inactivated IL-1/3). Survival is signifi­
cantly enhanced by IL-1 pretreatment in Swiss and in C3H/ 
HeN mice ix2 =  4.22 and 8.03, p <  0.05, and p <  0.005, 
respectively), but not in C3H/HeJ mice (23 to 28 mice/group).
FIGURE 2. Median plasma TNF-a concentrations in Swiss 
mice after i.m. K. pneumoniae infection in normal mice (■) 
or P. aeruginosa infection in neutropenic mice ( • )  (five mice 
per datum point).
Kruskal Wallis test (37). Probability values of less than 0.05 were con­
sidered significant. When n components were analyzed, the Bonferroni- 
corrected a  =  0.05/n was used as significance criterion.
Results
Specificity and validation o f RIAs for 
murine cytokines
Specificity of the three antisera was confirmed by assess­
ing the lack of displacement of tracer from the respective 
Ab by m r lL - la ,  mrIL-1/3, mrTNF-a, h r IL - la ,  hrIL-1/3, 
and hrTNF-a, all tested in concentrations up to 5 /txg/ml.
Sensitivities of the RIAs for m IL - la ,  mIL-1/3, and 
m TN F-a  with freshly prepared tracers ranged from 50 to
80, 20 to 70, and 80 to 140 pg/ml, respectively. The intra- Measurement o f in vivo cytokine production
mice and with Swiss mice. The responses of the mice were 
verified by the lack of rise in plasma T N F -a  levels 2 h 
after i.p. LPS (50 /xg) in C3H/HeJ mice, and a rise in 
C3H/HeN mice (39) (not shown). We examined survival 
and cytokine production in C3H/HeJ and C3H/HeN mice 
infected with P. aeruginosa.
As shown in Figure 1, pretreatment with 800 ng rhIL-1/3 
24 h before lethal P. aeruginosa infection enhanced sur­
vival significantly in neutropenic C3H/HeN and Swiss 
mice (x 1 = 4.33 and 8.03, p  < 0.05 and p < 0.005, respec­
tively), but only slightly in neutropenic C3H/HeJ mice (x2 = 
1.67, NS). Survival of infected mice not treated with IL-1 
was somewhat better in C3H/HeJ mice compared with un­
treated C3H/HeN mice (%2 = 2.78, p = 0.09). Survival of 
IL-1-pretreated C3H/HeN mice did not differ significantly 
from that in C3H/HeJ mice not treated with IL-1.
assay coefficient of variation was less than 15% from the 
detection limit to typically 1800 pg/ml ( IL - la  and IL-1/3) 
and 6000 pg/ml (TNF-a). Interassay precision, expressed 
as coefficient of variation, was estimated by measuring 
two different plasma concentrations of IL - la ,  IL-1/3, and 
T N F -a  (320 and 625 pg/ml) in duplicate on 10 different 
occasions, and was 15.0% and 12.9% for IL - la ,  3.8% and 
7.1% for IL-1/3, and 15.4% and 11.0% for TN F-a . Recov­
ery in these occasions was 91% and 98% for IL - la ,  87% 
and 94% for IL-1/3, and 91% and 112% for TN F-a , with 
SEM always <6 .3% . When supernatant from unstimu­
lated peritoneal macrophages was spiked with 160 or 320 
pg/ml m r lL - la ,  mrIL-1/3, and mrTNF-a, and measured on 
10 occasions, recovery was 111% and 94% for IL - la ,  
110% and 89% for IL-1/3, and 120% and 112% for 
TN F-a , with SEM always < 16% .
Effect o f  rhlL-1fi pretreatment on survival in different 
strains o f mice
Plasma concentrations of I L - l a  and IL-1/3 were at or be­
low the detection limit at each time point after an i.m. 
challenge with K. pneumoniae  (non-neutropenic mice) or 
P. aeruginosa (neutropenic mice).
As shown in Figure 2, plasma T N F -a  concentrations 
rose in Swiss mice at different time points in both types of 
infection. T N F -a  concentrations peaked at 1 h after K. 
pneumoniae inoculation, and then declined to the detection 
limit at 15 to 20 h. After P. aeruginosa injection, T N F-a  
levels were lower than after the K. pneumoniae challenge 
and peaked later (1900 pg/ml at 5 h). These differences 
seem to reflect the more indolent course of the P. aerugi­
nosa infection, because we and others have observed that 
if the same stimulus for TNF production is used in neu­
tropenic mice and normal mice, the former have higher 
TNF concentrations in their blood (Ref. 40 and M. G. 
Netea, J. W. M. van der Meer, W. L. Blok, G. Francot, and 
W. A. Buurman, manuscript in preparation).
The effect of rhIL-1/3 pretreatment on plasma TN F-a  
The LPS-hyporesponsive C3H/HeJ mice (38) were com- levels in Swiss mice after infection is shown in Figure 3. 
pared with the closely related LPS-sensitive C3H/HeN After a K. pneumoniae challenge, T N F -a  plasma levels in
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FIGURE 3. Plasma TNF-a concentrations in Swiss mice 
pretreated at - 2 4  h with 800 ng of IL-1/3 (hatched bar) or 
control pretreatment (inactivated IL-1 ß) (solid bar), and in­
fected at t =  0 with K. pneumoniae (normal mice; panel A) 
or P. aeruginosa (neutropenic mice; panel B). Differences 
with control mice are significant at 5 and 8 h after P. aerugi­
nosa infection (p  =  0.009 and p =  0.0043, respectively; 6 to 
10 mice/group).
IL-1-pretreated normal mice were lower, albeit not statis­
tically significant. In neutropenic P. aeruginosa-infected 
Swiss mice, T N F -a  levels in the IL-l-pretreated group 
were reduced at each time point (significant at 5 and 8 h, 
p = 0.009 and p = 0.0043, respectively).
In neutropenic C3H/HeJ mice pretreated with rhIL-1/3 
or control injections, plasma T N F -a  5 h after a P. aerugi­
nosa challenge was undetectable. In C3H/HeN mice, 
IL-1/3 pretreatment caused a significant reduction of 
T N F -a  levels at this time point (p  =  0.04); also, in Swiss 
mice examined in the same experiment this difference was 
highly significant (p  =  0.0015) (Fig. 4). In each strain of 
mice and in both pretreatment groups, T N F -a  levels were 
undetectable at 24 h.
IL-6 serum levels, measured 3 and 8 h after P. aerugi­
nosa infection in neutropenic Swiss mice, were reduced by 
IL-1 pretreatment (t =  3 h: from 6826 to 1736 U/ml, p = 
0.004; t =  8 h: from 2746 to 1463 U/ml, NS; 6 to 7 mice/ 
group).
Measurement o f cytokine production ex vivo
Because macrophages are principal sources of IL-1 and 
TN F-a , the effect of IL-1 pretreatment on cytokine pro-
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FIGURE 4. Effect of i.p. pretreatment at - 2 4  h with 800 ng 
of IL-1/3 (hatched bar ) or control pretreatment (inactivated 
IL-1 /3) (solid bar) on plasma TNF-a concentrations at 5 h after 
i.m. P. aeruginosa infection administered at time zero in neu­
tropenic Swiss, C3H/HEN, and C3H/HeJ mice. The reduction 
of TNF-a is significant in C3H/HeN mice (p  =  0.04) and in 
Swiss mice (p  =  0.0015), but not in C3H/HeJ mice (8 to 10 
mice/group).
penic mice (Fig. 5). These cells were removed from the 
mice and cultured for 24 h with or without LPS. No cy­
tokine production was detectable in cells or supernatants 
of cells from uninfected mice incubated without LPS, in­
dicating the absence of significant endotoxin contamina­
tion during cell isolation and culture (data not shown). In 
uninfected non-neutropenic Swiss mice, secreted T N F -a  
of LPS-stimulated peritoneal macrophages obtained 24 h 
after IL-1 or control pretreatment was significantly re­
duced in the group pretreated with IL-1 (p  =  0.01), 
whereas cell-associated I L - l a  after culture with LPS was 
nonsignificantly reduced (panel A). In similar experi­
ments with noninfected neutropenic Swiss mice, the same 
pattern was observed (panel B).
In peritoneal cells isolated from non-neutropenic Swiss 
mice 5 h after a K. pneumoniae challenge and cultured 
with LPS, cell-associated I L - l a  and secreted T N F -a  were 
significantly reduced when mice were pretreated with IL-1 
(p  =  0.01 and p = 0.017, respectively; panel C ). Basal 
T N F -a  secretion was present in unstimulated cells, which 
was also reduced by pretreatment with IL-1 (from 320 to 
170 pg/ml, p =  0.067) (data not shown).
In unstimulated and LPS-stimulated macrophages col­
lected 5 h after P. aeruginosa injection from neutropenic 
C3H/HeJ mice pretreated in vivo with rhIL-1/3 or vehicle 
treatment, cytokines were low or undetectable in cellular 
fractions and supernatants (panel D). In IL-l-pretreated 
C3H/HeN mice, peritoneal cells isolated 5 h after P. 
aeruginosa infection contained less intracellular I L - l a  
(p  =  0.014) and secreted less T N F -a  (p = 0.019) in com­
parison with cells from control mice (panel E ). Five hours 
after P. aeruginosa infection in neutropenic Swiss mice, 
cell-associated IL - la ,  and IL-1/3 and T N F -a  in superna­
tants after LPS stimulation were significantly reduced by 
in vivo IL-1 pretreatment (p  = 0.0048, p = 0.0076, and
duction capacity was studied with peritoneal macrophages p  =  0.024, respectively; panel F). In supernatants from 
from uninfected or infected non-neutropenic or neutro- unstimulated cells, low levels of spontaneous T N F -a  were
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FIGURE 5. Ex vivo measurements of cytokine concentrations in cultured LPS-stimulated supernatants (s) and cells (c) isolated 
from mice pretreated in vivo with IL-1/3 (hatched bar) or control pretreatment (inactivated IL-1/3) (solid bar) w ithout infection, 
or after infection with K. pneumoniae (normal mice) or P. aeruginosa (neutropenic mice) (4 to 8 mice/group). A  Macrophages 
isolated from non-neutropenic uninfected Swiss mice 24 h after in vivo pretreatments. Secreted TNF-a is significantly reduced 
after IL-1 pretreatment (p  = 0.01). B. Macrophages isolated from neutropenic uninfected Swiss mice 24 h after in vivo 
pretreatments. Secreted TNF-a is significantly reduced after IL-1 pretreatment (p  = 0.009). C. Macrophages isolated from 
non-neutropenic IL-1 or control pretreated Swiss mice 5 h after infection with K. pneumoniae. Cell-associated IL-1 a: and 
secreted TNF-a from LPS-stimulated cells are significantly reduced after IL-1 pretreatment (p  = 0.01 and p =  0.017, respec­
tively). D. Macrophages isolated from neutropenic IL-1 or control pretreated C3H/HeJ mice 5 h after infection with P. aerugi­
nosa. E. Macrophages isolated from neutropenic IL-1 or control pretreated C3H/HeN mice 5 h after infection with P. aerugi­
nosa. Cell-associated IL - la  and secreted TNF-a from LPS-stimulated cells are significantly reduced after IL-1 pretreatment (p  =
0.014 and p =  0.019, respectively). F. Macrophages isolated from neutropenic IL-1 or control pretreated Swiss mice 5 h after 
infection with P. aeruginosa. Cell-associated IL-1 a and secreted IL-1/3 and TNF-a from LPS-stimulated cells are significantly 
reduced after IL-1 pretreatment (p  = 0.0048, p =  0.0076, and p =  0.024, respectively). G. Macrophages isolated from 
neutropenic IL-1 or control pretreated C3H/HeJ mice 24 h after infection with P. aeruginosa. H. Macrophages isolated 
from neutropenic IL-1 or control pretreated C3H/HeN mice 24 h after infection with P. aeruginosa. I. Macrophages isolated 
from neutropenic IL-1 or control pretreated Swiss mice 24 h after infection with P. aeruginosa. Secreted TNF-a from LPS- 
stimulated cells is significantly reduced after IL-1 pretreatment (p  =  0.04).
present; however, these were still significantly reduced in cellular fractions or supernatants of unstimulated or stimu-
IL-l-pretreated cells (190 vs 140 pg/ml, p = 0.0059; data 
not shown).
Twenty-four hours after P. aeruginosa infection in control 
or IL-1-pretreated C3H/HeJ mice, cytokine concentrations in
lated macrophage cultures were negligible (panel G). Mac­
rophages from neutropenic C3H/HeN mice obtained 24 h 
after P. aeruginosa infection and cultured with LPS con­
tained cell-associated IL - la  concentrations of 1570 and 850
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Table I. Median expression of steady state mRNA of IL-IRa, IL-1RI, and TNFRI 12 and 24 h after IL-1 treatment
Organ Time (h)
IL-IRa IL-1 Rtl TNFRtl
Ratio* (n)** Range Ratio (n) Range Ratio (n) Range
Spleen 12 1.03 (2) 0 .9 -1 .1 6 0 .6 4 (3) 0 .5 5 - 0 .7 6 0.81 (3) 0 .7 8 -0 .8 4
24 1.83 (2 ) 1 .34-2 .31 0.65 (8 ) 0 .4 0 - 0 .8 4 0 .69 (9) 0 .3 0 - 0 .9 4
Thym us 12 0 .96 (1) 1.02 (1) 0 .87 (1)
24 0.93 (3) 0 .8 2 -1 .4 0.73 (3) 0 .6 3 -0 .9 0 .83 (3) 0 .4 4 -0 .8 6
Liver 12 1.46 (1) 0 .28 (2 ) 0 .0 8 - 0 .4 8 0 .36 (2 ) 0 .1 7 -0 .5 5
24 8.35 (2) 7 .4 5 -9 .2 5 1.5 (3) 0 .7 5 -2 .4 1 > 2 6 .3 (3) > 2 4 . 0 - > 2 8 . 7
Lung 12 1.05 (1) 0.86 (2 ) 0 .7 8 -0 .9 3 1.01 (1)
24 0.88 (1) 0 .65 (1) 0 .74 (1)
Kidney 12 1.14 (1) 1.0 (2 ) 0 .9 6 - 1 .0 4 0 .97 (2 ) 0 .8 9 - 1 .0 4
24 0 .94 (3) 0 .8 9 -0 .9 9 0 .98 (2 ) 0 .95 -1 1.73 (2 ) 1 .3 4 -2 .1 2
Brain 12 1.07 (1) 0 .95 (2) 0 .9 3 - 0 .9 6 0.73 (2 ) 0 .45 -1
24 0.95 (3) 0 .9 3 -1 .0 8 0 .98 (2 ) 0 .9 1 -0 .9 9 1.06 (4) 0 .6 4 -1 .0 9
* Ratios of densities of IL-1 Ra, IL-1 RI, or TNFRI mRNAs after IL-1 vs control pretreatment (inactivated IL-1 /3) are divided by the ratios of densities of 0-actin 
mRNA after IL-1 vs control pretreatment in the same blot.
** (/)) denotes the number of observations.
pg/ml in control and IL-1-treated mice, respectively (NS); 
TN F-a  secreted by these cells was only slightly reduced 
(panel H). In LPS-stimulated peritoneal macrophages from 
neutropenic Swiss mice 24 h after P. aeruginosa infection, 
IL-1 pretreatment reduced cell-associated IL-1 a: by 65% 
(/? =  0.04), and secreted TNF-a by 30% (NS) (panel I).
Effect o f  IL-1 pretreatment on IL-1Ra gene expression 
in organs
The steady state mRNA expression of the IL-IRa was not 
influenced by IL-1 pretreatment in any organ at early time 
points, but at 24 h a 1.8- and 9-fold up-regulation was present 
in spleen and liver, respectively (Table I and Fig. 6).
Effect o f  IL-1 pretreatment on IL-1RI and TNFRI 
gene expression
As shown in the dot blot (Fig. 6), a 60 and 54% down- 
regulation of steady state levels of mRNA for the IL-1RI 
and TNFRI, respectively, was found in the spleen 24 h 
after IL-1 pretreatment in comparison with control treat­
ment. In Table I, the results of steady state m RNA levels 
12 and 24 h after IL-1 pretreatment are shown for the 
various organs. A  down-regulation (± 3 0 % ) of steady state 
levels of mRNA for the IL-1RI and for the TNFRI were 
present in the spleen, thymus, and lung at 12 and 24 h after 
IL-1 pretreatment in comparison with control treatment, 
and no effect occurred in the brain. A  clear up-regulation 
of IL-1RI and TNFRI m RN A  was present in the liver at 
24 h after IL-1 pretreatment, following a down-regulation 
at 12 h. In the kidney, after a 12-h pretreatment there was 
no IL-1 effect; at 24 h an up-regulation was observed for 
the TNFRI but not for the IL-1RI.
Spleen
Discussion
control IL-1
IL -IR a
(3-Actin
IL-1RI
P-Actin
TNFRI
p-Actin
FIGURE 6. Effect of IL-1 treatment on steady state levels of 
IL-1 Ra, IL-1 Rl, and TNFR1 mRNA isolated from the spleen at 
24 h. Equivalent loading of the lanes was monitored by the 
constitutive expression of the /3-actin housekeeping gene.
tions in normal and neutropenic mice is associated with 
decreased circulating concentrations of T N F -a  and IL-6 
and reduced ex vivo production of IL-1 a  and T N F -a  by 
macrophages. In these same animals there was an up-reg- 
ulation of IL-IRa m RN A  in the liver and spleen. In par­
allel, a down-regulation of IL-1RI and T N F -a  receptor 
m RN A  occurs. These results support the concept that re­
duction of cytokine production or cytokine effects is ben­
eficial in serious infections (13, 41 -44 ) .
The role of IL-l-induced down-regulation of cytokine 
production in IL-l-induced enhanced survival was further
In the present study, we have shown that IL-l-induced examined in C3H/HeJ mice, which do not produce cyto-
enhancement of survival of lethal Gram-negative infec- kines after a challenge such as LPS. In C3H/HeJ mice,
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cytokine concentrations after a Gram-negative bacterial 
challenge are expected to be low. Therefore, if reduction 
of cytokine production would be the principal mechanism 
of IL-l-induced protection to infection, IL-l-induced en­
hanced survival should not occur in these mice. Our results 
are in accordance with this assumption. We observed a 
stepwise increase in survival to P. aeruginosa infection by 
IL-1 pretreatment in C3H/HeJ mice (nonsignificant), C3H/ 
HeN mice (significant), and Swiss mice (highly signifi­
cant). In the plasma of neulropcnic C3H/HeJ mice, 5 h 
after the P. aeruginosa challenge cytokines were not de­
tectable; in C3H/HeN mice, TNF-cv plasma concentrations 
were elevated, and significantly reduced by IL-1 pretreat­
ment; in Swiss mice, these effects of IL-1 pretreatment 
were even more pronounced. The increasing protective ef­
fect of IL-1 in C3H/HeJ, C3H/HeN, and Swiss mice, re­
spectively, is also parallelled by an increasing down-reg- 
ulation of cytokine production ex vivo.
The down-regulation of proinfiammatory cytokines by 
pretreatment with IL-1 seems to be associated with up- 
regulation of IL-IRa mRNA at the time of infection. IL- 
IRa inhibits many effects of IL-1 by blocking the IL-1R 
(45). Attenuation of IL-1 effects by IL-IRa during severe 
infections has been demonstrated (42, 46), and two recent 
studies demonstrate that administering neutralizing Abs to 
IL-IRa enhances the severity of disease (47, 48). Induc­
tion of IL-IRa synthesis in vitro by IL-1 has recently been 
reported (21-23, 49). Our finding of enhanced gene ex­
pression of IL-IRa in spleen and liver after IL-1 pretreat­
ment could imply that IL-IRa induction plays a role in 
IL-l-induced protection. Interestingly, a similar pattern,
i.e., down-regulation of proinfiammatory cytokines with 
up-regulation of IL-IRa occurs once infections such as 
meningococcal infection and typhoid fever have been es­
tablished (50, 51). It is likely that in natural overwhelming 
infections (such as meningococcal sepsis in humans) the 
protective down-regulation of cytokine production up-reg­
ulation of anti-inflammatory cytokines occurs too late.
In addition to the modulation of pro- and anti-inflam­
matory cytokine production, we also investigated whether 
a desensitization of target cells by down-regulation of re­
ceptors plays a role in the IL-l-induced enhanced survival 
of infection. This possibility has been suggested by several 
in vitro studies (24, 25), although this does not apply to all 
types of cells (52). Because of the low numbers of cyto­
kine surface receptors, we assessed steady state gene ex­
pression of the IL-1 RI and the TNFRI in organs of Swiss 
mice 24 h after IL-1 or control injection, which is the time 
of the infectious challenge.
IL-1 pretreatment induced a down-regulation in spleen, 
thymus, and lung levels of both IL-1 RI and TNFRI 
mRNA. These results suggest that IL-l-induced protection 
to infection is partially mediated by down-regulation of 
these receptors for IL-1 and TNF.
We have not been able to evaluate the effect of IL-1 on 
the type II IL-1R (IL-1RII). However, it is likely that this
receptor is of lesser biologic relevance, because it has been 
recently reported that IL-1 signaling occurs exclusively 
via the type I receptor (53). Also, the TNFRI seems to be 
of greater biologic relevance than the TNFRI I, because 
TNFRI-dependent signaling cascades have been proposed 
to be important in the effects of T N F -a  as a proinflamma- 
tory factor (54), and because mice deficient for the TNFRI 
arc resistant to septic shock (55).
In the liver, IL -1 RI and TNFRI mRNA steady state lev­
els were up-regulated at 24 h. The role of this up-regula­
tion is unclear for the IL-l-induced protection. On the 
other hand, it could be argued that this up-regulation at the 
level of the hepatocyte is beneficial by augmenting acute 
phase proteins (12). In addition, because IL-1 pretreatment 
ameliorates the biochemical and histologic signs of liver 
damage,3 increased IL-1R on hepatocytes may augment 
this effect. Receptor up-regulation may also enhance clear­
ance of IL-1 and T N F -a  and thus add to the reduction of 
plasma cytokine levels (56, 57). The observed TNFR up- 
regulation in the kidney could also contribute to clearance 
of T N F -a  (58).
Wallach et al. (19) also reported a protective effect of 
IL-1 pretreatment in galactosamine-sensitized mice to le­
thal effects of IL-1, TNF, and LPS. Similar to our obser­
vations, these investigators suggested that IL-l-induced 
protection is mediated by decreased cytokine production 
after LPS, and demonstrated decreased cytokine sensitiv­
ity of target cells. In contrast, Libert et al. (59), who stud­
ied the desensitization by IL-1 pretreatment to TNF and 
LPS in galactosamine-treated mice, did not observe re­
duced T N F -a  plasma concentrations or modulated surface 
T N F -a  receptors in the liver 12 h after IL-1 pretreatment. 
Because of the differences in the models used (especially 
the galactosamine sensitization), it is difficult to compare 
these results with ours.
Sheppard and Norton (60) reported protection by IL-1 
pretreatment to a lethal T N F -a  challenge and also sug­
gested desensitization of target cells as a mechanism. Con- 
tel, Parant, and Parant (61) observed decreased T N F-a  
levels after LPS administration in IL-l-pretreated mice. In 
ex vivo studies with macrophages, desensitization for LPS 
was observed for only 2 h; these authors suggest a role of 
in vivo-induced corticosterone in the T N F -a  down-regu­
lation. In our models, however, IL-l-induced glucocorti- 
costeroids do not play a role (10).
Although numerous studies report a deleterious role of 
overproduced cytokines during infection, physiologic 
quantities of TNF, IL-1, and IL-6 during infection may be 
protective (46, 62-64) .  Our recent studies with an anti­
murine T N F -a  mAb argue for a deleterious role of TN F-a  
in the rapidly lethal experimental infections studied (11). 
Further studies performed with the use of specific Abs
‘ Vogels, M. T. E., VV. M. C. Eling, A. Otten, and j. W. M. van der Meer. 
IL-1-induced resistance to bacterial infection: a role of the type 1 IL-1 receptor 
and amelioration of pathology. Submitted for publication.
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could confirm a causal role in reduction of these cytokines 
in our model of IL-l-induced protection.
In addition to modulation of inflammatory and anti-in- 
flammatory cytokines and cytokine receptors, other mech­
anisms of IL-1-induced protection could be operative. In­
duction of soluble TNFRs by IL-1, which neutralized 
TN F-a , has been reported in vivo (22). We have previ­
ously reported the role of IL-l-induced protective acute 
phase proteins (12). These proteins may be responsible for 
the slight protection induced by IL-1, which we observed 
in C3HHeJ mice. The mechanisms put forward in our 
studies might well be responsible for other IL-1-induced 
beneficial effects induced by IL-1 such as radiation pro­
tection, prevention of IL-2 toxicity, prevention of cytosine 
arabinoside-induced alopecia, and prevention of acetamin- 
ophen-induced liver damage (65-68).
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